Monte Rosa Therapeutics Inc (GLUE)

$7.74 +0.11 (1.44%)
Market Cap 478.02M
Revenue (ttm) 75.62M
Net Income (ttm) -72.70M
EPS (ttm) N/A
PE Ratio 21.19
Forward PE N/A
Profit Margin -96.14%
Debt to Equity Ratio 0.00
Volume 586,600
Avg Vol 1,241,838
Day's Range N/A - N/A
Shares Out 61.76M
Stochastic %K 93%
Beta 1.54
Analysts Strong Sell
Price Target $16.83

Company Profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of i...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 949 2643
Address:
321 Harrison Avenue, Suite 900, Boston, United States
G101SPM
G101SPM Oct. 3 at 4:45 PM
$GLUE $7.68 ask. BUY/NEW LONG POSITION carries SPM 87.99 tag to $10.00 in midterm.
1 · Reply
LabPsycho
LabPsycho Oct. 2 at 2:19 PM
$GLUE @biolover The criterion you mention are years / decades in the future and most of the outrageous revenue and market share estimates are phantasmagorically optimistic and consistently wrong IMO - and made up by a bunch of grifters at hedge funds just trying to suck money out of suckers. The chance of any arbitrary biotech ever getting a drug approved, getting revenues and being profitable are about 1-2%. That is why it is better IMO to evaluate current situation and likelihood for another move based on credibility of a company.
0 · Reply
Tnitty4371
Tnitty4371 Oct. 1 at 1:52 PM
$GLUE 🌋🌋🌋💵💵💵 $SPY $QQQ $TSLA $NVDA
0 · Reply
MuchMillions
MuchMillions Sep. 30 at 4:50 PM
$GLUE above $8 next week 💯
0 · Reply
highnihilism
highnihilism Sep. 30 at 10:31 AM
$SKLZ Skillz: 204 trades, $230K vs $16K avg (14.34x !!!!). $29K calls / $201K puts. $ODD Oddity Tech: 53 trades, $36K vs $357K avg (0.10x !!!!). $29K calls / $7K puts. $GLUE Monte Rosa Therapeutics: 35 trades, $32K vs $26K avg (1.23x). $29K calls / $3K puts. $YEXT Yext: 20 trades, $30K vs $32K avg (0.92x). $29K calls / $0.6K puts.
0 · Reply
biolover
biolover Sep. 30 at 3:07 AM
$GLUE $TNGX because This is not the way to evaluate biotechs. U look at drugs , sectors , TAM , potential revenues, chance of success. It is not about phase 1 vs 2 and partnership with NVS.
2 · Reply
ap20
ap20 Sep. 29 at 7:44 PM
$GLUE Added.
0 · Reply
ap20
ap20 Sep. 29 at 6:54 PM
$GLUE Break on through to the other side….
0 · Reply
Tnitty4371
Tnitty4371 Sep. 29 at 6:12 PM
$GLUE 🥹🥹💵💵🎁🎁 iykyk $SPY $QQQ $TSLA $NVDA
0 · Reply
Tnitty4371
Tnitty4371 Sep. 29 at 2:24 PM
$GLUE this will be a quiet storm 🎁💵📈💰🤑 $TSLA $NVDA $SPY $QQQ
0 · Reply
Latest News on GLUE
Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC

Sep 18, 2025, 9:25 AM EDT - 17 days ago

Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC

Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders

Sep 16, 2025, 10:56 AM EDT - 19 days ago

Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Sep 15, 2025, 7:00 AM EDT - 20 days ago

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Sep 2, 2025, 7:00 AM EDT - 4 weeks ago

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

Aug 7, 2025, 7:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Jul 21, 2025, 7:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

Jul 3, 2025, 2:15 PM EDT - 3 months ago

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Jun 10, 2025, 7:00 AM EDT - 4 months ago

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 7:00 AM EDT - 4 months ago

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

May 8, 2025, 7:00 AM EDT - 5 months ago

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

Apr 28, 2025, 7:00 AM EDT - 5 months ago

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 12:00 PM EDT - 7 months ago

Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Mar 11, 2025, 7:00 AM EDT - 7 months ago

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 7:00 AM EST - 7 months ago

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN

Feb 16, 2025, 8:26 PM EST - 8 months ago

Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 9 months ago

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Dec 13, 2024, 7:00 AM EST - 10 months ago

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Dec 11, 2024, 7:00 AM EST - 10 months ago

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Dec 11, 2024, 7:00 AM EST - 10 months ago

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Dec 5, 2024, 7:00 AM EST - 10 months ago

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 11 months ago

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

This Biotech Stock Has Doubled Its Value Today—Here's Why

Oct 28, 2024, 3:06 PM EDT - 1 year ago

This Biotech Stock Has Doubled Its Value Today—Here's Why

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

Jul 8, 2024, 8:36 AM EDT - 1 year ago

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

Jun 14, 2024, 8:45 AM EDT - 1 year ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 30, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

Monte Rosa Therapeutics Announces Leadership Team Promotions

May 30, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Leadership Team Promotions

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

May 21, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

May 16, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 15, 2024, 4:01 PM EDT - 1 year ago

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

May 2, 2024, 4:01 PM EDT - 1 year ago

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

Jan 8, 2024, 7:15 AM EST - 1 year ago

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

Nov 21, 2023, 7:00 AM EST - 2 years ago

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

Nov 7, 2023, 10:00 AM EST - 2 years ago

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

Monte Rosa Therapeutics: Roche Partnership Deal Could Bring Added Value

Oct 31, 2023, 8:56 AM EDT - 2 years ago

Monte Rosa Therapeutics: Roche Partnership Deal Could Bring Added Value

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

Oct 26, 2023, 4:30 PM EDT - 2 years ago

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

Oct 17, 2023, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

Oct 17, 2023, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:15 AM EDT - 2 years ago

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

Jul 26, 2023, 7:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

May 30, 2023, 4:30 PM EDT - 2 years ago

Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

G101SPM
G101SPM Oct. 3 at 4:45 PM
$GLUE $7.68 ask. BUY/NEW LONG POSITION carries SPM 87.99 tag to $10.00 in midterm.
1 · Reply
LabPsycho
LabPsycho Oct. 2 at 2:19 PM
$GLUE @biolover The criterion you mention are years / decades in the future and most of the outrageous revenue and market share estimates are phantasmagorically optimistic and consistently wrong IMO - and made up by a bunch of grifters at hedge funds just trying to suck money out of suckers. The chance of any arbitrary biotech ever getting a drug approved, getting revenues and being profitable are about 1-2%. That is why it is better IMO to evaluate current situation and likelihood for another move based on credibility of a company.
0 · Reply
Tnitty4371
Tnitty4371 Oct. 1 at 1:52 PM
$GLUE 🌋🌋🌋💵💵💵 $SPY $QQQ $TSLA $NVDA
0 · Reply
MuchMillions
MuchMillions Sep. 30 at 4:50 PM
$GLUE above $8 next week 💯
0 · Reply
highnihilism
highnihilism Sep. 30 at 10:31 AM
$SKLZ Skillz: 204 trades, $230K vs $16K avg (14.34x !!!!). $29K calls / $201K puts. $ODD Oddity Tech: 53 trades, $36K vs $357K avg (0.10x !!!!). $29K calls / $7K puts. $GLUE Monte Rosa Therapeutics: 35 trades, $32K vs $26K avg (1.23x). $29K calls / $3K puts. $YEXT Yext: 20 trades, $30K vs $32K avg (0.92x). $29K calls / $0.6K puts.
0 · Reply
biolover
biolover Sep. 30 at 3:07 AM
$GLUE $TNGX because This is not the way to evaluate biotechs. U look at drugs , sectors , TAM , potential revenues, chance of success. It is not about phase 1 vs 2 and partnership with NVS.
2 · Reply
ap20
ap20 Sep. 29 at 7:44 PM
$GLUE Added.
0 · Reply
ap20
ap20 Sep. 29 at 6:54 PM
$GLUE Break on through to the other side….
0 · Reply
Tnitty4371
Tnitty4371 Sep. 29 at 6:12 PM
$GLUE 🥹🥹💵💵🎁🎁 iykyk $SPY $QQQ $TSLA $NVDA
0 · Reply
Tnitty4371
Tnitty4371 Sep. 29 at 2:24 PM
$GLUE this will be a quiet storm 🎁💵📈💰🤑 $TSLA $NVDA $SPY $QQQ
0 · Reply
HellenJune
HellenJune Sep. 29 at 2:20 PM
$GLUE 10 by mid October?
0 · Reply
hellyeah1
hellyeah1 Sep. 29 at 4:39 AM
$GLUE Pretty cool stock. Good income and balance sheet. Let's see what it does for the next 10 days.
0 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 3:03 AM
$GLUE: Unusual Options Activity Alerted CALL flow observed 300x contracts at Strike price of $5 Exp on 10/17/2025 with Premium of $67K and showing BULLISH Sentiment
0 · Reply
Doozio
Doozio Sep. 27 at 3:17 PM
It was always during 🐒🍌🧠⏰♾️ wen all the DRUGzzzz included sniffing $GLUE
0 · Reply
MuchMillions
MuchMillions Sep. 27 at 12:45 AM
$GLUE this stock is so undervalued and under the radar it blows my mind. Would not be surprised at all if it has a 200-500% run in a single day
0 · Reply
MuchMillions
MuchMillions Sep. 26 at 7:07 PM
$GLUE setting up for a gap up monday?
1 · Reply
Tm13579
Tm13579 Sep. 26 at 6:31 PM
$GLUE looking like another tasty short opportunity here, I wouldn’t be surprised to see an offering announced at close with such an unnatural attempt at a pump
3 · Reply
DogDayDreaming
DogDayDreaming Sep. 26 at 6:08 PM
$GLUE I like how the stock is behaving. Consolidation after the big move earlier this month is now visible as having been really needed. Shareholder rotation for short-term and weaker hands.
1 · Reply
OnTheBalance
OnTheBalance Sep. 26 at 6:03 PM
$GLUE Puts going PUTZ
0 · Reply
heyupikachu1821
heyupikachu1821 Sep. 26 at 5:40 PM
$GLUE nice!! I’ve been so focused on $CRNX that I didn’t even realize we were rallying!
1 · Reply
Tnitty4371
Tnitty4371 Sep. 26 at 5:35 PM
$GLUE 💵💵💵💵📈📈📈 $SPY $NVDA $TSLA $QQQ early bird gets the worm
0 · Reply
arbwatson
arbwatson Sep. 26 at 4:34 PM
$GLUE nice move. Time to unglue the shorts.
0 · Reply